Comparative study of epidermal growth factor receptor mutation analysis on cytology smears and surgical pathology specimens from primary and metastatic lung carcinomas

Cancer Cytopathology

Volumn 121, Issue 7, 2013, Pages 361-369

  Khode, Renu ^a   Larsen, Douglas A ^a   Culbreath, Brianne C ^a   Parrish, Shane ^a   L walker, Kimberly ^a   Sayage Rabie, Lubna ^a   Beissner, Robert S ^a   Rao, Arundhati ^a  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

Author keywords

Cytology surgical correlation; Epidermal growth factor receptor; Pyromark q24; Rotor gene q

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FORMALDEHYDE; PARAFFIN; DNA; EGFR PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOLOGY; EXON; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CARCINOMA; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PYROSEQUENCING; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TISSUE PREPARATION; ADENOCARCINOMA; CYTODIAGNOSIS; CYTOLOGY SURGICAL CORRELATION; GENETICS; GENOTYPE; LUNG TUMOR; METASTASIS; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PYROMARK Q24; ROTOR-GENE Q; VERY ELDERLY;

CYTOLOGY SURGICAL CORRELATION; EPIDERMAL GROWTH FACTOR RECEPTOR; PYROMARK Q24; ROTOR-GENE Q;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CYTODIAGNOSIS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PARAFFIN EMBEDDING; PATHOLOGY, SURGICAL; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84884789641     PISSN: None     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.21273     Document Type: Article

References (38)

1. Centers for Disease Control and Prevention. Lung Cancer Statistics 2008. Atlanta, GA: 2008. Available at: http://www.cdc.gov/cancer/lung/statistics/ Accessed November 5, 2012.
2. Fathi AT, Brahmer JR. Chemotherapy for advanced stage nonsmall cell lung cancer. Semin Thorac Cardiovasc Surg. 2008;20:210-216.
3. D'Angelo SP, Park B, Azzoli CG, et al. Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: report on initial experience and clinical utility at a single center. J Thorac Cardiovasc Surg. 2011;141:476-480.
4. Gupta R, Dastane AM, Forozan F, et al. Evaluation of EGFR abnormalities in patients with pulmonary adenocarcinoma: The need to test neoplasms with more than 1 method. Mod Pathol. 2009;22:128-133.
5. Cohen S. Purification of the receptor for epidermal growth factor from A-431 cells: its function as a tyrosyl kinase. Methods Enzymol. 1983;99:379-387. (Pubitemid 13009545)
6. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res. 2003;284:31-53. (Pubitemid 36331965)
7. Wells A. Molecules in focus: EGF receptor. Int J Biochem Cell Biol. 1999;31:637-643.
8. Smouse JH, Cibas ES, Janne PA, Joshi VA, Zou KH, Lindeman NI. EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer. Cancer (Cancer Cytopathol). 2009;117:67-72.
9. Ladanyi M, Pao W. Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Mod Pathol. 2008;21:S16-S22. (Pubitemid 351592769)
10. Otani H, Toyooka S, Soh J, et al. Detection of EGFR gene mutations using the wash fluid of CT-guided biopsy needle in NSCLC patients. J Thorac Oncol. 2008;3:472-476. (Pubitemid 351630273)
11. Ettinger DS, Akerley W, Bepler G, et al. Non small cell lung cancer. J Natl Compr Canc Netw. 2010;8:740-801.
12. Keedy VL, Temin S, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol. 2011;29:2121-2127.
13. Eberhard DA, Giaccone G, Johnson BE. Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol. 2008;26:983-994. (Pubitemid 351398092)
14. Pao W, Ladanyi M. Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. Clin Cancer Res. 2007;13:4954-4955. (Pubitemid 47502057)
15. Ellison G, Donald E, McWalter G, et al. A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples [serial online]. J Exp Clin Cancer Res. 2010;29:132.
16. Ronaghi M, Uhlen M, Nyen P. A sequencing method based on real time pyrophosphate. Science. 1998;281:363-365. (Pubitemid 28340773)
17. Guo DC, Qi Y, He R, Gupta P, Milewicz DM. High throughput detection of small genomic insertions or deletions by pyrosequencing. Biotechnol Lett. 2003;25:1703-1707. (Pubitemid 37325526)
18. Takano T, Ohe Y, Sakamoto H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol. 2005;23:6829-6837.
19. Dufort S, Richard MJ, Lantuejoul S, de Fraipont F. Pyrosequencing, a method approved to detect the 2 major EGFR mutations for anti EGFR therapy in NSCLC [serial online]. J Exp Clin Cancer Res. 2011;30:57.
20. Querings S, Altmuller J, Ansen S, et al. Benchmarking of mutation diagnostics in clinical lung cancer specimens [serial online]. PLoS ONE. 2011;6:e19601.
21. Kimura H, Kasahara K, Kawaishi M, et al. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with nonsmall cell lung cancer. Clin Cancer Res. 2006;12:3915- 3921. (Pubitemid 44078075)
22. Billah S, Stewart J, Staerkel G, Chen S, Gong Y, Guo M. EGFR and KRAS mutations in lung carcinoma: molecular testing by using cytology specimens. Cancer (Cancer Cytopathol). 2011; 119:111-117.
23. Arcturus Bioscience, Inc. Arcturus PicoPure DNA Extraction Kit handbook. Mountain View, CA: Arcturus Bioscience, Inc.; 2012. Available at: http://search.cosmobio.co.jp/cosmo-search-p/search-gate2/docs/MOD-/KIT0103. 20090123.pdf Accessed July 10, 2012.
24. Zymo Research Corporation. Pinpoint Slide DNA Isolation System Instructions. Catalog no. D3001. Irvine, CA: Zymo Research Corporation; 2012. Available at: http://www.zymoresearch.com/media/downloads/16/D3001i.pdf. Accessed July 10, 2012.
25. Qiagen. EGFR Pyro Handbook. Valencia, CA: Qiagen; 2012. Available at: http://www.qiagen.com/selectlocation.aspx?redirect1/4%2fliterature%2frender. aspx%3fid%3d200796. Accessed July 10, 2012.
26. Qiagen. EGFR Rotor-Gene Q PCR Kit Handbook. Valencia, CA: Qiagen; 2012. Available at: www.qiagen.com/literature/render.aspx?id1/4201622 Accessed July 10, 2012.
27. Clark DP. Seize the opportunity: underutilization of fine needle aspiration biopsy to inform targeted cancer therapy decisions. Cancer (Cancer Cytopathol). 2009;117:289-297.
28. Chowdhuri SR, Xi L, Pham TH, et al. EGFR and KRAS mutation analysis in cytologic samples of lung adenocarcinoma enabled by laser capture microdissection. Mod Pathol. 2012;25: 548-555.
29. Sakurada A, Lara-Guerra H, Liu N, Shepherd FA, Tsao MS. Tissue heterogeneity of EGFR mutation in lung adenocarcinoma. J Thorac Oncol. 2008;3:527-529. (Pubitemid 351630282)
30. Kalikaki A, Koutsopoulos A, Trypaki M, et al. Comparison of EGFR and K-RAS gene status between primary tumors and corresponding metastases in NSCLC. Br J Cancer. 2008;99:923-929.
31. Schmid K, Oehl N, Wrba F, Pirker R, Pirker C, Filipits M. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin Cancer Res. 2009;15:4554-4560.
32. Riely GJ, Politi KA, Miller VA, Pao W. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res. 2006;12:7232-7241. (Pubitemid 46095394)
33. Marchetti A, Martella C, Felicioni L, et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol. 2005;23:857-865. (Pubitemid 46224186)
34. Killian JK, Walker RL, Suuriniemi M, et al. Archival fine-needle aspiration cytopathology (FNAC) samples: untapped resource for clinical molecular profiling. J Mol Diagn. 2010;12:739-745.
35. Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011;29:2866-2874.
36. Douillard JY, Shephard FA, Hirsh V, et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated nonsmall- cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol. 2010;28:744-752.
37. Horiike A, Kimura H, Nishio K, et al. Detection of epidermal growth factor receptor mutation in transbronchial needle aspirates of non-small cell lung cancer. Chest. 2007;131:1628-1634. (Pubitemid 46981613)
38. Lopez-Rios F, Angulo B, Gomex B, et al. Comparison of molecular testing methods for the detection of EGFR mutations in formalin- fixed paraffin-embedded tissue (FFPET) specimens of nonsmall cell lung cancer (NSCLC). Abstract 120. Paper presented at: European Society of Medical Oncology Third European Lung Cancer Conference; April 18-21, 2012; Geneva, Switzerland. 2012. Available at: http://www.dianasterapeuticas.com/web/pdf/ESMO-Handout-PR.pdf. Accessed July 16, 2012.